Broussard Cheryl S, Frey Meghan T, Hernandez-Diaz Sonia, Greene Michael F, Chambers Christina D, Sahin Leyla, Collins Sharp Beth A, Honein Margaret A
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA.
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Oak Ridge Institute for Science and Education, Oak Ridge, TN.
Am J Obstet Gynecol. 2014 Sep;211(3):208-214.e1. doi: 10.1016/j.ajog.2014.05.040. Epub 2014 May 29.
To address information gaps that limit informed clinical decisions on medication use in pregnancy, the Centers for Disease Control and Prevention (CDC) solicited expert input on a draft prototype outlining a systematic approach to evaluating the quality and strength of existing evidence for associated risks. The draft prototype outlined a process for the systematic review of available evidence and deliberations by a panel of experts to inform clinical decision making for managing health conditions in pregnancy. At an expert meeting convened by the CDC in January 2013, participants divided into working groups discussed decision points within the prototype. This report summarizes their discussions of best practices for formulating an expert review process, developing evidence summaries and treatment guidance, and disseminating information. There is clear recognition of current knowledge gaps and a strong collaboration of federal partners, academic experts, and professional organizations willing to work together toward safer medication use during pregnancy.
为填补限制孕期用药知情临床决策的信息空白,美国疾病控制与预防中心(CDC)就一份原型草案征求专家意见,该草案概述了一种评估相关风险现有证据质量和强度的系统方法。该原型草案概述了一个对现有证据进行系统综述并由专家小组进行审议的过程,以为孕期健康状况管理的临床决策提供依据。在2013年1月由CDC召集的一次专家会议上,分成若干工作组的与会者讨论了该原型中的决策点。本报告总结了他们关于制定专家评审流程、编写证据摘要和治疗指南以及传播信息的最佳做法的讨论。目前已明确认识到当前的知识空白,并且联邦合作伙伴、学术专家和专业组织愿意共同努力,以实现孕期更安全用药,各方展开了强有力的合作。